Sarepta Therapeutics
SRPT
13.33
-0.84
-5.93%
Sarepta Therapeutics
US · SRPT
#2853 by market cap
Listed 1970
13.33
-0.84
-5.93%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:54
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 6 in the most recent period (2026/Q3).
- Total institutional ownership fell 4.8 percentage points.
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 98.06% -4.79pp
- Institutions
- 385 -6
- As of
- 2026/Q3 vs. prior period
Holder types
Mutual Fund70.72%
Hedge Fund17.51%
Public Company5.80%
Individual/Insider4.70%
Private Company1.56%
Government Pension Fund1.44%
Insurance Company0.49%
VC/PE Fund0.45%
Top holders as of 2026-09-30
BlackRock
17.51% · 18.78M sh
Vanguard Portfolio Management, LLC
8.11% · 8.70M sh
State Street Global Advisors
6.91% · 7.41M sh
Vanguard Capital Management, LLC
4.29% · 4.60M sh
Two Sigma Investments, LP
4.29% · 4.60M sh
First Trust Advisors L.P.
4.07% · 4.37M sh
AQR Capital Management
3.98% · 4.27M sh
Richard Barry
3.00% · 3.22M sh
Geode Capital Management, LLC
2.51% · 2.69M sh
Erste Asset Management GmbH
2.12% · 2.27M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 26 buys · 24 sells
| Name | Role | Stake |
|---|---|---|
| Richard Barry | Independent Director | 3.00% |
| Michael Chambers | Independent Director | 0.45% |
| Douglas Ingram | Advisor | 0.36% |
| M. Behrens Wilsey | Independent Chairwoman | 0.19% |
| Louise Rodino-Klapac | President of Research & Development and Technical Operations | 0.19% |
| Ian Estepan | President | 0.17% |
| Ryan Wong | Chief Financial Officer | 0.11% |
| Cristin Rothfuss | -- | 0.11% |
| Claude Nicaise | Independent Director | 0.03% |
| Hans Wigzell | Chairman of Corporate Strategy Board & Independent Non-Employee Director | 0.02% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-03 | Louise Rodino-Klapac | President of Research & Development and Technical Operations | Sale to Issuer | -21,423 | $22.22 |
| 2026-09-03 | Ian Estepan | President | Sale to Issuer | -24,799 | $22.22 |
| 2026-09-03 | Cristin Rothfuss | -- | Sale to Issuer | -22,025 | $22.22 |
| 2026-09-03 | Ryan Wong | Chief Financial Officer | Sale to Issuer | -13,272 | $22.22 |
| 2026-07-27 | Michael Severino | Chief Executive Officer | Other Acquisition | +756,104 | -- |
| 2026-07-27 | Michael Severino | Chief Executive Officer | Other Derivative Acquisition | +2,224,342 | $17.74 |
| 2026-06-03 | M. Behrens Wilsey | Independent Chairwoman | Other Acquisition | +16,875 | -- |
| 2026-06-03 | Hans Wigzell | Chairman of Corporate Strategy Board & Independent Non-Employee Director | Other Acquisition | +16,875 | -- |
| 2026-06-03 | Richard Barry | Independent Director | Other Acquisition | +16,875 | -- |
| 2026-06-03 | Michael Chambers | Independent Director | Other Acquisition | +16,875 | -- |
| 2026-06-03 | Deirdre Connelly | Independent Director | Other Acquisition | +16,875 | -- |
| 2026-06-03 | Stephen Mayo | Independent Director | Other Acquisition | +16,875 | -- |
| 2026-06-03 | Claude Nicaise | Independent Director | Other Acquisition | +16,875 | -- |
| 2026-06-03 | Kathryn Boor | Independent Director | Other Acquisition | +16,875 | -- |
| 2026-03-11 | Stephen Mayo | Independent Director | Open Market Disposition | -7,239 | $17.02 |
| 2026-03-10 | Louise Rodino-Klapac | President of Research & Development and Technical Operations | Sale to Issuer | -948 | $17.03 |
| 2026-03-10 | Ian Estepan | President | Sale to Issuer | -1,097 | $17.03 |
| 2026-03-10 | Cristin Rothfuss | -- | Sale to Issuer | -974 | $17.03 |
| 2026-03-10 | Ryan Wong | Chief Financial Officer | Sale to Issuer | -256 | $17.03 |
| 2026-03-08 | Louise Rodino-Klapac | President of Research & Development and Technical Operations | Sale to Issuer | -1,399 | $16.95 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 19:54:28 · For reference only, not investment advice and not tailored to your situation.
Sarepta Therapeutics discussion 0 comments